Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment
Mei Huang, … , Marjan Azin, Shadmehr Demehri
Mei Huang, … , Marjan Azin, Shadmehr Demehri
Published October 16, 2023
Citation Information: J Clin Invest. 2023;133(20):e166494. https://doi.org/10.1172/JCI166494.
View: Text | PDF
Research Article Oncology

Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment

  • Text
  • PDF
Abstract

Carcinogen exposure is strongly associated with enhanced cancer immunogenicity. Increased tumor mutational burden and resulting neoantigen generation have been proposed to link carcinogen exposure and cancer immunogenicity. However, the neoantigen-independent immunological impact of carcinogen exposure on cancer is unknown. Here, we demonstrate that chemical carcinogen-exposed cancer cells fail to establish an immunosuppressive tumor microenvironment (TME), resulting in their T cell–mediated rejection in vivo. A chemical carcinogen-treated breast cancer cell clone that lacked any additional coding region mutations (i.e., neoantigen) was rejected in mice in a T cell–dependent manner. Strikingly, the coinjection of carcinogen- and control-treated cancer cells prevented this rejection, suggesting that the loss of immunosuppressive TME was the dominant cause of rejection. Reduced M-CSF expression by carcinogen-treated cancer cells significantly suppressed tumor-associated macrophages (TAMs) and resulted in the loss of an immunosuppressive TME. Single-cell analysis of human lung cancers revealed a significant reduction in the immunosuppressive TAMs in former smokers compared with individuals who had never smoked. These findings demonstrate that carcinogen exposure impairs the development of an immunosuppressive TME and indicate a novel link between carcinogens and cancer immunogenicity.

Authors

Mei Huang, Yun Xia, Kaiwen Li, Feng Shao, Zhaoyi Feng, Tiancheng Li, Marjan Azin, Shadmehr Demehri

×

Figure 6

Carcinogen exposure reprograms TAMs in mouse and human lung cancer.

Options: View larger image (or click on image) Download as PowerPoint
Carcinogen exposure reprograms TAMs in mouse and human lung cancer.
(A) ...
(A) LLC-DMBA and LLC-DMSO tumor growth in WT mice (n = 6 for LLC-DMBA and n = 10 for LLC-DMSO group). (B) Representative flow cytometric analysis of LLC-DMBA and LLC-DMSO TAMs in the tumors from WT mice. Numbers on the dot plots represent the percent cells within each gate. (C) F4/80+ leukocyte (TAM) frequencies in LLC-DMBA and LLC-DMSO tumors (n = 6 per group). (D) CD11b+ F4/80+ leukocyte (TAM) frequencies in LLC-DMBA and LLC-DMSO tumors (n = 6 per group). (E) CD11b MFI on LLC-DMBA and LLC-DMSO TAMs (n = 6 per group). (F) MHCII MFI on LLC-DMBA and LLC-DMSO TAMs (n = 6 per group). (G) M-CSF protein levels in LLC-DMBA compared with LLC-DMSO cell lysates (n = 4 per group). (H) t-stochastic neighbor embedding (t-SNE) plot of immune cells (n = 12,391) isolated from human non-small cell lung cancer tissues, including B cells: M, memory B cells; B cells-PB, plasmablast; pDCs, plasmacytoid DCs; MF, Monocytes, macrophages and monocytes; unknown, unknown cells from general clustering of all cells. (I) Carcinogen-induced TAM (n = 712) and classical TAM (n = 544) subsets of macrophages (n = 1,256) in human non-small cell lung cancer tissues. Carcinogen-induced TAMs are distinguished from classical TAMs by upregulation of CXCL9, CXCL10, CXCL11, PRF1, and GZMB and downregulation of ARG1, NT5E, TGM2, and IL4I1 genes as defined in Figure 4L. (J) Carcinogen-induced and classical TAM distribution in lung cancers of former smokers versus individuals who have never smoked (never smokers). 2-way ANOVA (A), unpaired t test (C–G) and χ2 test (J), bar graphs show mean + SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts